The relative risk of death in tumor patients was 3.2 times that of patients with low GSTP1 expression, and the relative risk of death in patients with GSTP1 expression in glioma nuclei was 3.9 times that in patients without GSTP1 expression in the nucleus (Ali-Osman et al., 1997). Here, GSTP1 is linked to neoplasm.